title: Opportunities and challenges in the era of molecularly targeted agents and radiation therapy.
abstract: The first annual workshop for preclinical and clinical development of radiosensitizers took place at the National Cancer Institute on August 8-9, 2012. Radiotherapy is one of the most commonly applied and effective oncologic treatments for solid tumors. It is well recognized that improved clinical efficacy of radiotherapy would make a substantive impact in clinical practice and patient outcomes. Advances in genomic technologies and high-throughput drug discovery platforms have brought a revolution in cancer treatment by providing molecularly targeted agents for various cancers. Development of predictive biomarkers directed toward specific subsets of cancers has ushered in a new era of personalized therapeutics. The field of radiation oncology stands to gain substantial benefit from these advances given the concerted effort to integrate this progress into radiation therapy. This workshop brought together expert clinicians and scientists working in various disease sites to identify the exciting opportunities and expected challenges in the development of molecularly targeted agents in combination with radiation therapy.
authors.affiliation: Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 097, Houston, TX 77030, USA. shlin@madanderson.org
authors.forename: Steven H
authors.initials: SH
authors.lastname: Lin
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: George
authors.forename: Edgar
authors.initials: E
authors.lastname: Ben-Josef
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Bradley
authors.forename: Kevin S
authors.initials: KS
authors.lastname: Choe
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Edelman
authors.forename: Chandan
authors.initials: C
authors.lastname: Guha
authors.forename: Sunil
authors.initials: S
authors.lastname: Krishnan
authors.forename: Theodore S
authors.initials: TS
authors.lastname: Lawrence
authors.forename: Quynh-Thu
authors.initials: QT
authors.lastname: Le
authors.forename: Bo
authors.initials: B
authors.lastname: Lu
authors.forename: Minesh
authors.initials: M
authors.lastname: Mehta
authors.forename: David
authors.initials: D
authors.lastname: Peereboom
authors.forename: Jann
authors.initials: J
authors.lastname: Sarkaria
authors.forename: Jinsil
authors.initials: J
authors.lastname: Seong
authors.forename: Dian
authors.initials: D
authors.lastname: Wang
authors.forename: Meng X
authors.initials: MX
authors.lastname: Welliver
authors.forename: C Norman
authors.initials: CN
authors.lastname: Coleman
authors.forename: Bhadrasain
authors.initials: B
authors.lastname: Vikram
authors.forename: Stephen
authors.initials: S
authors.lastname: Yoo
authors.forename: Christine H
authors.initials: CH
authors.lastname: Chung
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D017321:Clinical Trials, Phase I as Topic; D003226:Congresses as Topic; D016371:Cranial Irradiation; D006801:Humans; D053208:Kaplan-Meier Estimate; D058990:Molecular Targeted Therapy / Q000379:methods*; D054547:National Cancer Institute (U.S.); D009369:Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D057285:Precision Medicine / Q000639:trends*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D012107:Research Design; D012109:Research Support as Topic; D012720:Severity of Illness Index; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011838:Radiation-Sensitizing Agents